Author

J. L. Gulley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:imaging· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1

Frequent Co-Authors

A. Rajan· 2 shared C. Allen· 2 shared J. Strauss· 2 shared S. Bailey· 2 shared W. Lassoued· 2 shared A. Beuve· 1 shared A. C. Lockhart· 1 shared A. G. Sowalsky· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Rajan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Deep Learning Model Imputes Missing Stains in Multiplex Images

M. Shaban, W. Lassoued, K. Canubas, S. Bailey, Y. Liu, C. Allen, J. Strauss, J. L. Gulley, S. Jiang, F. Mahmood, G. Zaki, H. A. Sater

The paper introduces a deep learning model, MAXIM, to impute missing protein markers in multiplex images, improving efficiency in staining and imaging processes.

bioRxiv · Nov 21, 2023 · PreprintPathology

The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance

P. Rai, L. Zhang, C. I. Troccoli, B. Mateo-Victoriano, L. Misiara, E. N. Jackson, P. Shu, T. M. Plastini, W. Tao, D. Kwon, X. Chen, J. Sharma, M. Jorda, J. L. Gulley, M. Bilusic, , A. Beuve

This study identifies the soluble guanylyl cyclase (sGC) pathway as a target for castration-resistant prostate cancer (CRPC) treatment, showing that riociguat inhibits CRPC growth and enhances radiation response.

bioRxiv · May 3, 2023 · PreprintCancer Biology

Prediction of cancer treatment response from histopathology images through imputed transcriptomics

D.-T. Hoang, G. Dinstag, L. C. Hermida, D. S. Ben-Zvi, E. Elis, K. Caley, S.-J. Sammut, S. Sinha, N. Sinha, C. H. Dampier, C. Stossel, T. Patil, A. Rajan, W. Lassoued, J. Strauss, , E. Ruppin

ENLIGHT-DeepPT predicts cancer treatment response from H&E slides by first imputing transcriptomics and then using that data to predict response across multiple therapies and cancer types.

bioRxiv · Jun 7, 2022 · PreprintCancer Biology

Contrasting autoimmune and treatment effects reveals baseline set points of immune toxicity following checkpoint inhibitor treatment

C. Zhao, M. P. Mule, A. J. Martins, I. Pinal-Fernandez, R. N. Donahue, J. Chen, J. Schlom, J. L. Gulley, A. Mammen, J. S. Tsang, A. Rajan

The paper identifies pre-treatment immune signatures associated with immune-related adverse events (irAEs) in thymic cancer patients receiving checkpoint inhibitors using CITE-seq.

bioRxiv · Jun 5, 2022 · PreprintImmunology